Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
Pharvaris N.V. ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent h...